NASDAQ:GLPG Galapagos (GLPG) Stock Price, News & Analysis $27.48 +0.09 (+0.33%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$27.25▼$27.4950-Day Range$24.78▼$29.6352-Week Range$24.78▼$44.25Volume52,003 shsAverage Volume121,298 shsMarket Capitalization$1.81 billionP/E RatioN/ADividend YieldN/APrice Target$34.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Galapagos alerts: Email Address Galapagos MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside25.5% Upside$34.50 Price TargetShort InterestBearish2.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.41 to ($0.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.87 out of 5 starsMedical Sector844th out of 936 stocksPharmaceutical Preparations Industry397th out of 436 stocks 2.8 Analyst's Opinion Consensus RatingGalapagos has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageGalapagos has received no research coverage in the past 90 days.Read more about Galapagos' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.42% of the float of Galapagos has been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Galapagos has recently decreased by 2.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGalapagos does not currently pay a dividend.Dividend GrowthGalapagos does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLPG. Previous Next 2.2 News and Social Media Coverage News SentimentGalapagos has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Galapagos this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galapagos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Galapagos is held by insiders.Percentage Held by InstitutionsOnly 32.46% of the stock of Galapagos is held by institutions.Read more about Galapagos' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Galapagos are expected to decrease in the coming year, from $0.41 to ($0.08) per share.Price to Book Value per Share RatioGalapagos has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galapagos' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Galapagos Stock (NASDAQ:GLPG)Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Read More GLPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLPG Stock News HeadlinesJune 25, 2024 | investorplace.comGLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024June 14, 2024 | globenewswire.comGalapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 30, 2024 | globenewswire.comGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsMay 16, 2024 | globenewswire.comGalapagos creates new subscription right plansMay 15, 2024 | msn.comGalapagos, BCA to collaborate on CAR-T cell therapy productionMay 15, 2024 | tmcnet.comGalapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.May 15, 2024 | globenewswire.comGalapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 6, 2024 | finance.yahoo.comGalapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call TranscriptMay 5, 2024 | markets.businessinsider.comKepler Capital Sticks to Their Hold Rating for Galapagos (GLPG)May 4, 2024 | finance.yahoo.comGalapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)May 2, 2024 | globenewswire.comGalapagos reports first quarter 2024 financial resultsApril 30, 2024 | finance.yahoo.comGalapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024April 30, 2024 | globenewswire.comGalapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024April 4, 2024 | globenewswire.comGalapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024April 1, 2024 | msn.comGalapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: AnalystApril 1, 2024 | finance.yahoo.comGalapagos Full Year 2023 Earnings: Beats ExpectationsSee More Headlines Receive GLPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLPG CUSIPN/A CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,123Year Founded1999Price Target and Rating Average Stock Price Target$34.50 High Stock Price Target$38.00 Low Stock Price Target$31.00 Potential Upside/Downside+25.5%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.91 Quick Ratio9.70 Sales & Book Value Annual Sales$259.40 million Price / Sales6.98 Cash Flow$0.66 per share Price / Cash Flow41.81 Book Value$45.92 per share Price / Book0.60Miscellaneous Outstanding Shares65,900,000Free Float63,979,000Market Cap$1.81 billion OptionableOptionable Beta0.22 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Paulus A. Stoffels M.D. (Age 62)Ph.D., CEO, Chairman, Interim Head of R&D Comp: $1.34MMr. Thad Huston (Age 53)Executive VP, CFO & COO Ms. Sofie Van GijselHead of Investor RelationsMs. Valeria Cnossen (Age 50)Executive VP & General Counsel Marieke VermeerschHead of Corporate CommunicationMs. Annelies Missotten (Age 51)Executive VP & Chief Human Resources Officer Ms. Ellen Van Der AarHead of DevelopmentMr. Philippe Alen M.B.A.Ph.D., Pharm.D., Senior VP & Head of Business DevelopmentMr. Dirk De NaeyerHead of Development OperationsMs. Alice DietrichHead of Medical AffairsMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANSummit TherapeuticsNASDAQ:SMMTMadrigal PharmaceuticalsNASDAQ:MDGLCytokineticsNASDAQ:CYTKView All CompetitorsInstitutional OwnershipAlphaCentric Advisors LLCBought 3,500 shares on 7/26/2024Ownership: 0.165%BVF Inc. ILSold 51,300 shares on 5/16/2024Ownership: 2.828%Acadian Asset Management LLCBought 2,366 shares on 5/10/2024Ownership: 0.023%Monaco Asset Management SAMBought 10,000 shares on 5/9/2024Ownership: 0.025%Headlands Technologies LLCBought 712 shares on 5/8/2024Ownership: 0.001%View All Institutional Transactions GLPG Stock Analysis - Frequently Asked Questions How have GLPG shares performed this year? Galapagos' stock was trading at $40.65 at the start of the year. Since then, GLPG shares have decreased by 32.4% and is now trading at $27.48. View the best growth stocks for 2024 here. How were Galapagos' earnings last quarter? Galapagos NV (NASDAQ:GLPG) announced its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.51. The biotechnology company had revenue of $67.79 million for the quarter, compared to analyst estimates of $69.04 million. What is Onno van de Stolpe's approval rating as Galapagos' CEO? 6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Galapagos IPO? Galapagos (GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are Galapagos' major shareholders? Galapagos' top institutional investors include AlphaCentric Advisors LLC (0.16%). How do I buy shares of Galapagos? Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Galapagos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV) and Biogen (BIIB). This page (NASDAQ:GLPG) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
